Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1221-1230 of 2787 for cancer

Edit search filters
  1. A Study to Investigate the Effects of GC4419 on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer

    Jacksonville, FL

  2. Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

    Rochester, MN

  3. 68GaFAPI-46 PET/CT for Pancreatic Ductal Adenocarcinoma

    Rochester, MN

  4. A Study to See if Ultrasound Shear Wave Elastography Can Find Early Heart Muscle Damage from Chemotherapy in Cancer Patients

    Rochester, MN

  5. A Study of TRK-950 in Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ

  6. Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  7. A Study Evaluating the Addition of Venetoclax (ABT-199) to Patients with Multiple Myeloma who are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Rochester, MN

  8. Comparison of Operation to Monitoring With/Without Endocrine Therapy For Low Risk DCIS

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  9. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    Jacksonville, FL

  10. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer